Kuros Biosciences AG
SIX:KURN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zhejiang Century Huatong Group Co Ltd
SZSE:002602
|
CN |
|
S
|
Shanghai Shunho New Materials Technology Co Ltd
SZSE:002565
|
CN |
|
BOC Hong Kong Holdings Ltd
HKEX:2388
|
HK |
|
Shenzhen Jame Technology Corp Ltd
SZSE:300868
|
CN |
Kuros Biosciences AG
Total Current Liabilities
Kuros Biosciences AG
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Current Liabilities
CHf42.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Current Liabilities
$70.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Current Liabilities
$149.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
31%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Current Liabilities
CHf49.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Current Liabilities
CHf160.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Current Liabilities
CHf3.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
Glance View
Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
See Also
What is Kuros Biosciences AG's Total Current Liabilities?
Total Current Liabilities
42.1m
CHF
Based on the financial report for Dec 31, 2025, Kuros Biosciences AG's Total Current Liabilities amounts to 42.1m CHF.
What is Kuros Biosciences AG's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
61%
Over the last year, the Total Current Liabilities growth was 61%. The average annual Total Current Liabilities growth rates for Kuros Biosciences AG have been 50% over the past three years , 61% over the past five years .
